$EIQ (+1,99%) Echo IQ is a publicly traded Australian medtech/AI company (ASX: EIQ) specializing in cardiac diagnostic software (EchoSolv HF/AS)The company is in the clinical validation and FDA approval phase (no significant revenue yet), financed through capital increases and interest income from cash reserves.
A capital increase took place recently, and the company is currently rolling out its product in the U.S. As a result, the company is transitioning from a clinical developer to a commercial player.
The latest figures are from the half-year report in December:
https://api.investi.com.au/api/announcements/eiq/b4443306-1fa.pdf
Brief overview of key figures (comparison of H1 2025/26 vs. H1 2024/25):
Income Statement
- Revenue: 90,909 AUD (previous year: 101,409 AUD)
- Other income (primarily interest): 299,809 AUD (previous year: 172,345 AUD)
- Loss after taxes: AUD 8,659,669 (prior year: AUD 6,215,645) – loss increased significantly
- Major cost drivers: Personnel expenses of 2,578,557 AUD, equity-based compensation of 2,883,442 AUD, consulting and professional fees of 1,619,637 AUD
- Loss per share: -1.34 cents (prior year: -1.09 cents)
Balance Sheet (as of Dec. 31, 2025 vs. June 30, 2025)
- Cash and cash equivalents: AUD 11,212,499 (vs. AUD 6,617,702) – increase
- Time deposits/deposits: AUD 2,000,000 (vs. AUD 11,518,288) – significant decrease (maturity realized)
- Intangible assets: 4,416,654 AUD (vs. 4,686,945 AUD)
- Total assets: 17,988,519 AUD (vs. 23,372,338 AUD)
- Total Liabilities: 718,606 AUD (vs. 615,414 AUD) – minimal, no financial liabilities
- Equity (net assets): 17,269,913 AUD (vs. 22,756,924 AUD) – decrease of approximately 24%
Cash Flow
- Operating cash flow: -5,181,712 AUD (previous year: -3,410,633 AUD) – higher cash outflow
- Investing Activities: +9,491,151 AUD (primarily from the maturity of time deposits)
- Financing activities: +287,735 AUD (capital increase, significantly lower than the previous year’s 6.64 million AUD)
- Cash and cash equivalents at the end of the period: 11,212,499 AUD (previous year: 5,351,566 AUD)
Four analysts currently rate the stock as a “Strong Buy.”
10 million AUD flowed in from the partnership $PME (-1,15%) —in which some members of this community have invested. @Investingyoung
@thewolfofxetra
Another 10 million AUD is expected to be provided following FDA approval.
Does anyone in the community know this company and have an opinion? Perhaps a volatile bet for our @Multibagger ?
